Research library

Key finding

During a 168-week open-label extension in Barth syndrome, elamipretide was associated with a cumulative 96.1-metre improvement in six-minute walk distance, lower fatigue scores and improved cardiac-volume measures.

Key finding

In myocardial tissue cultures from young and aged rats, Cardiogen and selected amino acids increased cellular proliferation.

Key finding

In the randomized MMPOWER-3 trial, elamipretide was well tolerated but did not improve six-minute walk distance or fatigue scores versus placebo at 24 weeks.

Key finding

In senescent rats bearing M-1 sarcoma, Cardiogen administration was associated with higher tumour-cell apoptosis than control treatment.

Key finding

In mice, elamipretide reduced mitochondrial dysfunction, oxidative stress and neuroinflammation while improving synaptic structure, learning and memory after lipopolysaccharide exposure.

Key finding

The study reports that this mitochondrial plasticity is reduced in many age-associated diseases.

Key finding

The study reports that further research may expand its application to other diseases involving mitochondrial dysfunction as well as investigate long-term efficacy and safety of the drug.